STEP-1 Trial: A Plain-English Overview of What It Established
At a glance
| Detail | Value | |---|---| | Full title | Once-Weekly Semaglutide in Adults with Overweight or Obesity | | Registry | NCT03548935 | | N | 1,961 (semaglutide 1,306; placebo 655) | | Intervention | Subcutaneous semaglutide 2.4 mg once weekly | | Comparator | Matched placebo injection, both arms with lifestyle intervention | | Duration | 68 weeks (16-week dose escalation + 52-week maintenance) | | Primary endpoint | Percent change in body weight from baseline to week 68 | | Key result | −14.9% semaglutide vs −2.4% placebo (estimated treatment difference −12.4 percentage points; p < 0.001) | | Co-primary endpoint | Proportion achieving ≥5% weight loss: 86.4% vs 31.5% | | Published | February 2021, New England Journal of Medicine |
The question STEP-1 set out to answer
Before 2021, approved anti-obesity medications produced average weight loss in the range of 5% to 10%. Bariatric surgery could deliver 20% to 30%, but surgery carries its own risks and is not accessible to most patients. The STEP-1 trial asked a straightforward question: can a once-weekly injection of semaglutide at a higher dose (2.4 mg, above the 1.0 mg dose already approved for type 2 diabetes) produce weight loss that closes the gap between medications and surgery?
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1. It slows gastric emptying, reduces appetite through hypothalamic signaling, and lowers caloric intake. The drug was already well characterized at lower doses for glucose control. STEP-1 tested the weight-loss ceiling at a dose 2.4 times higher than the diabetes indication, in people without diabetes.
Who was enrolled (and who was not)
The trial recruited 1,961 adults across 129 sites in 16 countries. Eligibility required a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. Critically, the trial excluded people with type 2 diabetes, a design choice that isolated the weight-loss signal from confounding glucose-lowering effects.
Participants averaged 46 years old and had a mean baseline body weight of 105 kg (about 231 lb). Roughly 74% were women. The racial composition skewed heavily white (75%), with smaller representation of Asian (12%), Black (6%), and other groups. That demographic profile limits generalizability and is worth noting when applying results to broader populations.
People with a history of bariatric surgery, active eating disorders, or recent use of other weight-loss medications were excluded. So were those with a history of pancreatitis or personal/family history of medullary thyroid carcinoma (a boxed-warning concern for all GLP-1 receptor agonists, per the FDA label).
What participants actually did for 68 weeks
Both groups received the same lifestyle intervention: counseling to reduce caloric intake by 500 kcal/day and to perform at least 150 minutes per week of physical activity. This was not a drug-versus-nothing comparison. It was drug-plus-lifestyle versus placebo-plus-lifestyle.
The semaglutide arm started at 0.25 mg weekly and escalated over 16 weeks to the target dose of 2.4 mg. This slow ramp was designed to reduce gastrointestinal side effects, which are the most common reason patients stop GLP-1 drugs. Injections were self-administered subcutaneously, typically in the abdomen, thigh, or upper arm.
Randomization was 2:1 (semaglutide to placebo), meaning for every two participants getting the active drug, one received a visually identical placebo injection. Both participants and investigators were blinded.
HealthRX Weight-Loss Efficacy Ladder
To put STEP-1 results in context, we developed a simple reference ladder comparing mean percent body weight loss across major anti-obesity interventions studied in randomized trials:
| Tier | Intervention | Typical mean weight loss | Source | |---|---|---|---| | Tier 1 | Lifestyle alone | 2% to 4% | Multiple RCTs | | Tier 2 | Orlistat, naltrexone-bupropion, phentermine-topiramate | 5% to 10% | FDA labels | | Tier 3 | Liraglutide 3.0 mg (Saxenda) | 8% | SCALE trial | | Tier 4 | Semaglutide 2.4 mg (STEP-1) | 14.9% | Wilding et al. 2021 | | Tier 5 | Tirzepatide 15 mg (SURMOUNT-1) | 22.5% | Jastreboff et al. 2022 | | Tier 6 | Bariatric surgery (sleeve/bypass) | 25% to 35% | Meta-analyses |
STEP-1 placed semaglutide 2.4 mg firmly in a new tier between older medications and surgery, a gap that no approved drug had previously occupied.
Results: what the numbers actually showed
The primary endpoint
At week 68, participants on semaglutide lost a mean of 14.9% of their body weight, compared with 2.4% in the placebo group. The estimated treatment difference was −12.4 percentage points (95% CI, −13.4 to −11.5; p < 0.001). In absolute terms, the semaglutide group lost an average of 15.3 kg (about 33.7 lb) versus 2.6 kg (about 5.7 lb) for placebo.
Categorical weight-loss thresholds
The proportion of participants reaching clinically meaningful weight-loss thresholds tells a more granular story:
| Threshold | Semaglutide | Placebo | |---|---|---| | ≥5% weight loss | 86.4% | 31.5% | | ≥10% weight loss | 69.1% | 12.0% | | ≥15% weight loss | 50.5% | 4.9% | | ≥20% weight loss | 32.0% | 1.7% |
One in three patients on semaglutide lost at least 20% of their body weight. Before this trial, that degree of weight loss from a medication was essentially unheard of in published RCT data. The STEP-1 publication reported these as co-primary and confirmatory secondary endpoints, all reaching statistical significance.
Secondary outcomes
The trial measured a broad set of cardiometabolic markers. Semaglutide produced greater reductions in waist circumference (−13.5 cm vs −4.1 cm), systolic blood pressure (−6.2 mmHg vs −1.1 mmHg), C-reactive protein, and lipid markers including triglycerides. These secondary endpoints suggest that the weight loss was accompanied by metabolic improvement beyond the scale, though the trial was not powered to detect differences in hard cardiovascular outcomes like heart attack or stroke. That question was later addressed in the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg.
Safety: what went wrong and how often
Gastrointestinal adverse events dominated the safety profile. Nausea occurred in 44.2% of semaglutide participants versus 17.4% on placebo. Diarrhea (31.5% vs 15.9%), vomiting (24.8% vs 6.2%), and constipation (24.2% vs 10.1%) were also more common. Most of these events were mild to moderate in severity and occurred primarily during the 16-week dose-escalation phase.
Discontinuation due to adverse events was 7.0% in the semaglutide group versus 3.1% in the placebo group. That means roughly 93 out of every 100 participants on semaglutide tolerated the drug well enough to stay in the trial. Serious adverse events occurred in 9.8% of semaglutide participants and 6.4% of placebo participants.
Gallbladder-related events (cholelithiasis, cholecystitis) affected 2.6% of semaglutide participants versus 1.2% on placebo. Rapid weight loss from any cause increases gallstone risk, and this is a known class concern. There were no cases of pancreatitis confirmed as related to the study drug, and no thyroid C-cell tumors were reported, though the trial's 68-week duration limits conclusions about long-term rare events.
Methodological strengths and honest limitations
What the trial did well
The 2:1 randomization and double-blind design were rigorous. The sample size of nearly 2,000 provided statistical power to detect differences across multiple subgroups. The 68-week duration was long by anti-obesity drug trial standards, though still short relative to the lifelong nature of obesity as a chronic disease. Retention was reasonable: 90.8% of participants completed the trial, and 81.1% were still on treatment at week 68.
Where the trial falls short
No diabetes patients. Excluding type 2 diabetes limits the applicability to the population that most commonly uses GLP-1 drugs. The STEP-2 trial later studied semaglutide 2.4 mg specifically in people with type 2 diabetes and found lower weight loss (about 9.6%), partly because glucose utilization changes the metabolic response.
Industry-sponsored. Novo Nordisk funded the trial, employed several authors, and was involved in trial design and data analysis. This does not invalidate the results, but it is standard practice to note the potential for bias.
Short follow-up relative to chronic disease. Obesity is a lifelong condition. A 68-week trial tells you what happens during treatment but not what happens after. The STEP-1 extension study showed that participants who stopped semaglutide regained about two-thirds of the weight they had lost within one year, underscoring that the drug manages obesity rather than curing it.
Limited diversity. With 75% white participants and 74% women, the results may not fully represent outcomes in men, Black, Hispanic, or other underrepresented populations. Subgroup analyses did not reveal differential treatment effects by sex or race, but subgroup analyses are inherently underpowered for that purpose.
No body composition data by DEXA. The trial measured weight and waist circumference but did not report lean mass versus fat mass changes. Subsequent smaller studies have suggested that roughly 30% to 40% of weight lost on GLP-1 drugs is lean mass, which raises questions about muscle preservation, particularly in older adults.
What STEP-1 means for clinical practice today
The FDA approved semaglutide 2.4 mg (branded as Wegovy) for chronic weight management in June 2021, largely on the basis of the STEP-1 through STEP-4 trial program. The approval covered adults with a BMI ≥30 or ≥27 with at least one comorbidity, mirroring the trial's enrollment criteria.
STEP-1 shifted the clinical conversation about obesity treatment. Professional societies including the American Gastroenterological Association now include semaglutide 2.4 mg as a first-line pharmacotherapy option for obesity management. The trial also set a benchmark that subsequent drugs (tirzepatide, retatrutide, survodutide) have used as their comparator floor.
For prescribers, STEP-1 established several practical expectations: weight loss begins within the first few weeks and continues progressively through about 60 weeks before plateauing. Nausea is most common during dose escalation and usually resolves. And perhaps most importantly, the trial confirmed that weight regain after discontinuation is the norm, not the exception, framing obesity pharmacotherapy as a long-term commitment.
Frequently asked questions
›
›
›
›
›
›
›
›
›
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. June 2021. FDA Label
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed